Клиническое значение лабораторных нарушений при системной красной волчанке

Тип работы:
Реферат
Предмет:
Медицина


Узнать стоимость

Детальная информация о работе

Выдержка из работы

СОВРЕМЕННАЯ РЕВМАТОЛОГИЯ № 2'14
ЛЕКЦИИ
(In Russ.)]. DOI: http: //dx. doi. org/10. 14 412/1995−4484−2013−1246.
13. Gill MJ, Quisel AM, Rocca P, Walters DT Diagnosis of systemic lupus erythematosus. Am Fam Physician. 2003−68(11): 2179−86.
14. Dipti TR, Azam MS, Sattar MH,
Rahman SA. Detection of anti-nuclear antibody by immunofluorescence assay and enzyme immunoassay in childhood systemic lupus erythematosus: experience from Bangladesh. Int J Rheum Dis.
2012−15(1): 121−5. DOI: 10. 1111/j. 1756−185X. 2011. 1 694.x. Epub 2011 Nov 30.
15. Solomon DH, Kavanaugh AJ, Schur PH- American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002−47(4): 434−44. DOI: http: //dx. doi. org/10. 1002/art. 10 561.
16. Sjowall C, Sturm M, Dahle C, et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. J Rheum. 2008−35(10): 1994−2000. Epub 2008 Sep 1.
17. Ardoin SP, Pisetsky DS. Developments in the scientific understanding of lupus. Arthritis Res Ther. 2008−10(5): 218. DOI: 10. 1186/ar2488. Epub 2008 Oct 10.
18. Isenberg D. Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus. Lupus.
2004−13(11): 881−5. DOI: http: //dx. doi. org/10. 1191/96 120 3304lu2028oa.
19. Bertsias G, Ioannidis J, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010−69(12): 2074−82. DOI: 10. 1136/ard. 2010. 130 476. Epub 2010 Aug 19.
20. Попкова Т В, Лисицына Т А. Рекомендации по ведению больных системной красной волчанкой в клинической практике (по материалам рекомендаций Европейской антиревматической лиги — EULAR). Современная ревматология. 2011-(1): 4−12. [Popkova TV, Lisitsyna TA. Rekomendatsii po vedeniyu bol'-nykh sistem-noy krasnoy volchankoy v klinicheskoy prak-tike (po materialam rekomendatsiy Evropeyskoy antirevmaticheskoy ligi — EULAR). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2011-(1): 4−12. (In Russ.)]. DOI: http: //dx. doi. org/ 10. 14 412/1996−7012−2011−645.
21. Madison PJ, Mogavero H, Reichin M. Pattern of clinical disease associated with antibodies to nuclear riboprotein. J Rheum. 1978−5(4): 407−11.
22. Hichon CA, Peschken CA. Sm antibodies increase risk of death in systemic lupus ery-
thematosus. Lupus. 2007−16(3): 186−94.
23. Насонов Е. Антифосфолипидный синдром. Москва: Литтерра- 2004. 440 с. [Nasonov E. Antifosfolipidnyi sindrom [Antifosfolipidny syndrome]. Moscow: Litterra- 2004. 440 p. ]
24. Ho A, Barr SG, Magder LS, Petri M.
A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001−44(10): 2350−7. DOI: http: //dx. doi. org/10. 1002/1529−0131(200 110)44:10%3C2350:AID-ART398%3E3.0. CO-2-A.
25. Manson JJ, Ma A, Rogers P, et al. Relationship between anti-dsDNA, anti-nucleosome and anti-alfa-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther. 2009−11(5): R154. DOI: 10. 1186/ar2831.
26. Ng KP, Manson JJ, Rahman A,
Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 2006−55(6): 900−4. DOI: http: //dx. doi. org/10. 1002/art. 22 356.
27. Sinico RA, Radice A, Ikehata M, et al. Anti-C1q autoantibodies in lupus nephritis. Prevalence and clinical significance. Ann NY Acad Sci. 2005−1050: 193−200. DOI: http: //dx. doi. org/10. 1196/annals. 1313. 020.
28. Meyer OC, Nicaise-Roland P, Cadoudal N, et al. Anti-G1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Res Ther. 2009−11(3): R87. DOI: 10. 1186/ar2725. Epub 2009 Jun 10.
29. Цанян М Э, Александрова Е Н, Соловьев С К, Насонов Е Л. Антитела к C1q при системной красной волчанке — биологический маркер активности, предиктор развития нефрита и неблагоприятного жизненного прогноза. Научно-практическая ревматология. 2013−51(1): 71−5. [Tsanyan ME, Aleksandrova EN, Solovyev SK, Nasonov EL. Anti-C1q antibodies in systemic lupus erythematosus are a biological marker of the activity of nephritis, a predictor for its development and a poor life prognosis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013−51(1): 71−5. (In Russ.)]. DOI: http: //dx. doi. org/10. 14 412/1995−4484−2013−1205.
30. Hepbum AL, Narat S, Mason JC.
The management of peripheral blood cytope-nias in systemic lupus erythematosus. Rheumatology (Oxford).
2010−49(12): 2243−54. DOI: 10. 1093/ rheumatology/keq269. Epub 2010 Sep 7.
31. Giannouli S, Voulgarelis M, Ziakas PD, Tzioufas AG. Anaemia in systemic lupus erythematosus: From pathophysiology to clinical
assessment. Ann Rheum Dis. 2006−65(2): 144−8. DOI: http: //dx. doi. org/10. 1136/ard. 2005. 41 673. Epub 2005 Aug 3.
32. Schur PH. Laboratory evaluation of patients with systemic lupus erythematosus. In: Lahita R. Systemic lupus erythematosus, 5th ed. 2011. P. 629−54. DOI: http: //dx. doi. org/10. 1016/B978−0-12−374 994−9. 10 034−8.
33. Kuwana M, Kaburaki J, Okazaki Y, et al. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006−45(7): 851−4. DOI: http: //dx. doi. org/10. 1093/rheumatology/kel0 10. Epub 2006 Jan 17.
34. Vila LM, Alarcon GS, McGwin JrG,
et al. Reveille, Systemic lupus erythematosus in a multiethnic U.S. cohort, XXXVII: Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual. Arthritis Rheum. 2006−55: 799−806. DOI: http: //dx. doi. org/10. 1002/art. 22 224.
35. Ng WL, Chu CM, Wu AK, et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. QJM.
2006 Jan-99(1): 37−47. DOI: http: //dx. doi. org/10. 1093/qjmed/hci155.
36. Dvorkina O, Ginzler EM. Corticosteroid and nonsteroid anti-inflammatory drug use in systemic lupus erythematosus. In: Lahita R. Systemic lupus erythematosus. 5th ed. 2011. P 1045−60. DOI: http: //dx. doi. org/ 10. 1016/B978−0-12−374 994−9. 10 056−7.
37. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore). 2006−85(3): 147−56.
DOI: http: //dx. doi. org/10. 1097/01. md. 224 709. 70 133. f7.
38. Murakami M, Tsubata T, Shinkura R,
et al. Acute lupus hemophagocytic syndrome: report of a case. Nefrologia. 2010−30(2): 247−51.
39. Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009−18(3): 257−63. DOI: 10. 1177/961 203 308 100 481.
40. Batnes EV, Narain S, Naranjo A, et al. High sensitivity C-reactive protein on systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus.
2005−14(8): 576−82. DOI: http: //dx. doi. org/ 10. 1191/96 120 3305lu2157oa.
41. Williams RC, Harmon ME,
Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheum. 2005−32(3): 454−61.

ПоказатьСвернуть
Заполнить форму текущей работой